Certara, Inc. · NASDAQ:CERT
Certara — Technical Presentation (March 2015)
42 slides from Certara's technical presentation, March 2015
Slide 1: How Do We Translate Preclinical and Clinical Research Into Labelling
How Do We Translate Preclinical and Clinical Research Into Labelling Karen Rowland Yeo Senior Scientific Advisor & Principal Consultant Karen.Yeo@certara.com
Slide 2: Outline
Outline •Introduction to PBPK modelling •System and drug related parameters •Integration of inter-individual variability •Labelling examples including PBPK modelling •Case studies •Relevant in vitro and clinical data •Model development © Copyright 2012 Certara, L.P. All rights reserved. 2
Slide 3: Separating Systems & Drug Information
Separating Systems & Drug Information Systems Drug Trial Data Data Design Age MW Weight LogP Dose Tissue Volumes pKa Route Tissue Composition Protein Binding Frequency Cardiac Output BP ratio Co-administered Drugs Tissue Blood Flows In vitro data: Populations [Plasma Protein] Metabolism Permeability
Slide 4: Model Selection
Model Selection Lumped minimal model OR Full PBPK Model Lung PO Small Intestine Generic Adipose ka Bone Single Adjusting Portal Vein Compartment Brain (SAC) Heart Arterial Venous Blood Kidney Blood kout kin Muscle Skin Systemic Liver Liver IV Compartment Spleen Portal Vein Gut IV Dose EHC PO Dose Fi
Slide 5: The Challenge of Population Variability
The Challenge of Population Variability Environment Disease Genetics © Copyright 2012 Certara, L.P. All rights reserved.
Slide 6: The Complexity of Covariates
The Complexity of Covariates Genotypes (Distribution in Population) Renal Function Body Ethnicity Disease Fat Serum Creatinine Sex Age (Distribution in Population) (Distribution in Population) Height Brain Body Volume Heart Surface Volume MPPGL Area HPGL Weight S9PPGL CPPGL Cardiac Cardiac Liver Out
Slide 7: Organs/Tissue Distributions
Organs/Tissue Distributions Frequency Frequency Size of Liver Size of Lungs Frequency Size of Stomach Frequency Size of GI Tract Frequency Size of Heart © Copyright 2012 Certara, L.P. All rights reserved.
Slide 8: Monte Carlo (MC) versus Correlated Monte Carlo (CMC)
Monte Carlo (MC) versus Correlated Monte Carlo (CMC) A randomly generated Randomly generated subjects subject using MC sampling using CMC sampling © Copyright 2012 Certara, L.P. All rights reserved.
Slide 9: Separating Systems & Drug Information
Separating Systems & Drug Information Systems Drug Trial Data Data Design Age MW Dose Weight LogP Administration route Tissue Volumes pKa Frequency Tissue Composition Protein binding Co-administered drugs Cardiac Output BP ratio Populations Tissue Blood Flows In vitro Metabolism [Plasma Protein] Per
Slide 10: PBPK Model-Influenced Drug Label Approvals
PBPK Model-Influenced Drug Label Approvals Company Drug Name Indication Studies Cited Revatio (Sildenafil) Pulmonary Arterial Hypertension 1 Deep Vein Thrombosis and Pulmonary Embolism – Xarelto (Rivaroxaban) hip/knee replacement and surgery 4 Edurant (Rilpivirine) HIV infection 1 Iclusig (Ponatinib
Slide 11: Eluglistat - Labelling
Eluglistat - Labelling Co-administration of CERDELGA with CYP2D6 Inhibitors Systemic exposure (Cmax and AUCtau) of eliglustat increased 7.0-fold and 8.4-fold, respectively, following co-administration of CERDELGA 84 mg twice daily with paroxetine (a strong CYP2D6 inhibitor) 30 mg once daily in EMs (
Slide 12: Complex DDIs Involving Multiple Components
Complex DDIs Involving Multiple Components CYP2D6 CYP3A4 CLR • Clinical DDIs studies for paroxetine and ketoconazole in CYP2D6 EM subjects. • PBPK model can be verified using clinical data to get the CYP3A4 and CYP2D6 contributions correct • CYP2D6 abundance data required for different phenotypes –
Slide 13: Dose Recommendations in CYP2D6 EM Subjects
Dose Recommendations in CYP2D6 EM Subjects © Copyright 2012 Certara, L.P. All rights reserved.
Slide 14: Dose Recommendations in CYP2D6 PM Subjects
Dose Recommendations in CYP2D6 PM Subjects © Copyright 2012 Certara, L.P. All rights reserved.
Slide 15: Case Study - Aripiprazole
Case Study - Aripiprazole Key information: CYP2D6 (major) and CYP3A substrate Model development – in vitro data and clinical PK data Model verification – 2 clinical DDI studies in CYP2D6 EM subjects (ketoconazole & quinidine) Model verification – Exposure of drug in CYP2D6 EM, IM and PM subjects Mod
Slide 16: Clinical DDI Study with Ketoconazole in CYP2D6 EM Subjects
Clinical DDI Study with Ketoconazole in CYP2D6 EM Subjects 15 mg oral aripiprazole dose on day 2 of 15 days of dosing with ketoconazole (200 mg BID) Control Plus ketoconazole Predicted AUC Ratio – 1.6 Observed AUC Ratio - 1.6 © Copyright 2012 Certara, L.P. All rights reserved.
Slide 17: Clinical DDI Study with Quinidine in CYP2D6 EM Subjects
Clinical DDI Study with Quinidine in CYP2D6 EM Subjects 10 mg oral aripiprazole dose on day 1 of 15 days of dosing with quinidine (166 mg QD) Control Plus quinidine Predicted AUC Ratio – 1.7 Observed AUC Ratio - 2.1 © Copyright 2012 Certara, L.P. All rights reserved.
Slide 18: Aripiprazole Exposure in CYP2D6 PM Subjects
Aripiprazole Exposure in CYP2D6 PM Subjects Aripirazole exposure in PMs - 15 mg oral dose Observed CLpo – 1.91 L/h Predicted CLpo – 1.90 L/h. © Copyright 2012 Certara, L.P. All rights reserved.
Slide 19: Css of Oral Aripiprazole – CYP2D6 EM, IM & PM
Css of Oral Aripiprazole – CYP2D6 EM, IM & PM Cmax at steady state Cmax Ratios (ng/ml) Trial (n=12) EM IM PM IM/EM PM/EM Trial 1 36.5 45.4 60.5 1.24 1.66 Trial 2 29.0 36.5 52.7 1.26 1.82 Trial 3 27.5 35.4 51.8 1.29 1.88 Trial 4 38.5 46.4 59.1 1.21 1.53 Trial 5 29.2 37.5 56.6 1.28 1.94 Trial 6 26.8 3
Slide 20: Ibrutinib
Ibrutinib Key information: CYP3A substrate CL/F = 1000 L/h Susceptibility to DDI is high Model development – in vitro data and clinical PK data Model verification – 2 clinical DDI studies (ketoconazole & rifampin) Model application – Untested clinical DDI scenarios (moderate CYP3A inhibitors and ind
Slide 21: Ibrutinib
Ibrutinib © Copyright 2012 Certara, L.P. All rights reserved. 21
Slide 22: Ibrutinib – Wording in the Label
Ibrutinib – Wording in the Label Drug Interactions Coadministration of Ibrutinib with CYP3A Inhibitors Simulations using physiologically-based pharmacokinetic (PBPK) models suggested that moderate CYP3A inhibitors (diltiazem and erythromycin) may increase the AUC of ibrutinib 6 to 9-fold in fasted c
Slide 23: Can PBPK Provide Dose Optimisation Strategy? CYP3A Inhibitors
Can PBPK Provide Dose Optimisation Strategy? CYP3A Inhibitors Recommended dose is 560 mg (QD) Highest dose evaluated (840-1400 mg) – safety issues “Reduce IMBRUVICA dose to 140 mg if a moderate CYP3A inhibitor must be used (e.g., fluconazole, darunavir, erythromycin, diltiazem, atazanavir, aprepitan
Slide 24: Can PBPK Provide Dose Optimisation Strategy? CYP3A Inducers
Can PBPK Provide Dose Optimisation Strategy? CYP3A Inducers Recommended dose is 560 mg (QD) Efficacy data – 140 mg “Avoid concomitant use of strong CYP3A inducers (e.g., carbamazepine, rifampin, Dose (mg) phenytoin and St. John’s Wort). Consider alternative agents with less CYP3A induction” © Copyri
Slide 25: Another Application – Effect of Dose Staggering
Another Application – Effect of Dose Staggering © Copyright 2012 Certara, L.P. All rights reserved. 25
Slide 26: Enzyme Activity after Multiple Doses of a Competitive Inhibitor
Enzyme Activity after Multiple Doses of a Competitive Inhibitor Simulated ketoconazole plasma concentration after multiple dose (50 mg b.i.d) and related change in liver CYP3A activity 0.8 100 Ketoconazole Concentration (mg/L) 0.7 0.6 75 % Enzyme activity 0.5 0.4 50 0.3 0.2 25 0.1 0. 0 0 0 24 48 72
Slide 27: Other Recommendations in the Review
Other Recommendations in the Review • “We noticed that you used PBPK modeling to predict drug- drug interactions for Ibrutinib. • You should further investigate the potential PK differences between healthy subjects and oncology subjects (for example under fasted condition) with respect to formulatio
Slide 28: Drug X - In Vitro Data
Drug X - In Vitro Data •Metabolic data for HLM, hepatocytes and rCYPs CYP3A4 substrate •fmCYP3A4 (70-80%) •fu – for a range of concentrations •MW, log P, B:P ratio, pKa •Caco-2 permeability data •Inactivation data for CYP3A4 (kinact and KI) Time dependent inhibitors of CYP3A4 (both parent and prim
Slide 29: Drug X – Clinical Study Data in HV
Drug X – Clinical Study Data in HV • Objectives – Safety, tolerability, PK and PD following single and repeat oral dosing – Food effect – Drug-drug interaction: effect of CYP3A4 inhibition • 4-part study Part 1: Single Part 2: Multiple Part 3: Food Part 4: Drug Ascending Dose Ascending Dose Effect I
Slide 30: Development of Model for Drug X and M1
Development of Model for Drug X and M1 DRUG X 1- fa Faeces Gut Lumen Oral Dose M1 fa 1- FG(m) 1- FG Metabolites M1 Metabolites Gut Wall Gut Wall Metabolite Portal Vein Portal Vein C(m)PV CPV Non –M1 Metabolites FG (m) FG QPV QPV QPV QPV QHA QHA Systemic FH (m) FH Systemic Liver M1 Liver Compartment
Slide 31: Model Development – Single Dose
Model Development – Single Dose Drug X M1 Simulated (lines) and observed (circles) mean plasma concentration-time profiles of Drug X after a single oral dose. The grey lines represent the outcomes of simulated individual trials (10 x 9) and the solid black line is the mean data for simulated the pop
Slide 32: Prediction of Time Dependent Inhibition
Prediction of Time Dependent Inhibition [S] [P] Rsyn [E·S] (zero order rate) [E] Kdeg (first order [E·I] rate) [I] kinact [PI] Drug X [E·MI] M1 Accelerated Deactivation Rowland Yeo et al., Eur J Pharm Sci 2011 © Copyright 2012 Certara, L.P. All rights reserved.
Slide 33: Complex Drug Drug Interaction
Complex Drug Drug Interaction TIME DEPENDENT INHIBITION COMPETITIVE INHIBITION Drug X M1 Ketoconazole AUTO-INHIBITION © Copyright 2012 Certara, L.P. All rights reserved.
Slide 34: Model Verification – DDI Study with Ketoconazole
Model Verification – DDI Study with Ketoconazole Predicted and observed (n=16) median AUC ratios after a single oral dose of Drug X administered on the 4th day of 5 days of dosing of ketoconazole (200 mg BID). © Copyright 2012 Certara, L.P. All rights reserved. 34
Slide 35: Ceretinib Example
Ceretinib Example Ceritinib is primarily metabolized by CYP3A, and is also a reversible and time-dependent inhibitor of CYP3A in vitro. Coadministration of ketoconazole (a strong CYP3A inhibitor) 200 mg twice daily for 14 days and a single dose of 450 mg ceritinib increased ceritinib AUC by 2.9-fold
Slide 36: Application of PBPK Modelling – Oncology Patients
Application of PBPK Modelling – Oncology Patients Jones & Rowland Yeo, CPT: Pharmacometrics & Systems Pharmacology (2013) © Copyright 2012 Certara, L.P. All rights reserved.
Slide 37: Oncology Population – Age Related Changes
Oncology Population – Age Related Changes 800 Oncology 600 400 Renal Function 200 0 Serum Creatinine Age Plasma Proteins (Distribution in Population) Height Body Surface Area Weight MPPGL HPGL Cardiac Cardiac Liver Output Index Volume Liver Intrinsic Weight Clearance Cheeti et al., 2012 © Copyright
Slide 38: Oncology Population - Impact of Disease on Protein Binding
Oncology Population - Impact of Disease on Protein Binding PT [P] fu HV 0 0.5 1 1.5 AAG levels (g/L) PT [P] fu HV 0 20 40 60 Albumin levels (g/L) Cheeti et al., 2012 © Copyright 2012 Certara, L.P. All rights reserved. 38
Slide 39: Model Validation – Multiple Dosing in Oncology Patients
Model Validation – Multiple Dosing in Oncology Patients Drug X M1 Simulated (lines) and observed (circles) mean plasma concentration-time profiles of Drug X after multiple dosing. The grey lines represent the outcomes of simulated individual trials (10 x 16) and the solid black line is the mean data
Slide 40: Model Application – DDI Study with Ketoconazole
Model Application – DDI Study with Ketoconazole Dose Dependent AUC Ratio X mg SD Drug X 4.1 Observed data in HV 2.5X mg BID Drug X 1.5 Prediction in patients 7.5X mg BID Drug X 1.3 Prediction in patients X mg QD Drug X 7.5X mg BID Drug X Active CY3A4 remaining after dosing of drug X Active CY3A4 rem
Slide 41: Summary
Summary • Possible to develop a robust PBPK model to accurately predict clinical exposure of a drug • relevant in vitro data • some clinical PK data to develop the model • some clinical DDI data to verify the model • A validated model can be applied to untested scenarios • Predictions from PBPK mode
Slide 42: Acknowledgement: The Simcyp Team
Acknowledgement: The Simcyp Team THANK YOU FOR YOUR ATTENTION!! © Copyright 2012 Certara, L.P. All rights reserved.